Key Scientific Publications - Nventa Biopharmaceuticals Corp.

Key Publications
Heat Shock Protein technology and Nventa Biopharmaceuticals' immunotherapeutics are cited in the following publications:

(NB: Nventa Biopharmaceuticals Corporation was formerly known as Stressgen Biotechnologies Corporation)

Efficacy of Heat Shock Protein-Based Therapy for Carcinoma-In-Situ of the Cervix

Mark H. Einstein, Anna S. Kadish, Robert D. Burk, Mimi Y. Kim, Scott S. Wadler, Howard Streicher, Gary L. Goldberg, Carolyn D. Runowicz.
Montefiore Medical Center, Bronx, NY, Albert Einstein College of Medicine, Bronx, NY, Albert Einstein Cancer Center, Bronx, NY, Weill-Cornell Medical Center, New York, NY, National Cancer Institute/Cancer Therapy Evaluation Program, Bethesda, MD, University of Connecticut- Neag Cancer Center, Farmington, CT

Presented at the 37th Annual Meeting of the Society of Gynecological Oncologists in San Diego

Download PDF files of the presentation posters

Systemic T Lymphocyte Responses to HPV 16 E6 and E7 peptides and Local Cervical Inflammatory Changes in Women with CIN III Treated with Heat Shock Protein-Based Immunotherapy

Mark H. Einstein, Lydia Tesfa, Aileen Caceres, Gary L. Goldberg, Anna S. Kadish.
Montefiore Medical Center, Bronx, NY, Albert Einstein College of Medicine, Bronx, NY

Abstract presented at The Society of Gynecologic Oncologists 2005 Annual Meeting on Women's Cancer, March 21, 2005

Heat Shock Protein (HSP)-Based Immunotherapy (HspE7) for Treatment of CIN III (NCI 5850): A Trial of the New York Phase II Consortium

Abstract presented at the Keystone Symposia: Basic Aspects of Tumor Immunology held in Keystone, CO March 19 th to 24 th , 2005

Memory CD8+ T cells induced by HspE7 fusion protein provide protection against tumor challenge

Poster presented at the 12th International Congress of Immunology, July 22, 2004

Induction of CD-4-independent CD8+ Memory T Cells by HspE7 Fusion Protein

Abstract presented at the 12th International Congress of Immunology, July 22, 2004

Induction of CD-4-independent CD8+ Memory T Cells by HspE7 Fusion Protein

J Immunol 2004; 172:2885-2893

A Role for Toll-like Receptor 4 in Dendritic Cell Activation and Cytolytic CD8+ T Cell Differentiation in Response to a Recombinant Heat Shock Fusion Protein.

J Immunol 2004; 172:3415-3421.

Myeloid Differentiation Factor 88 Is Required for Cross-Priming In Vivo.

The inter or intra-observational incongruities in pathologic studies concerning various states of neoplasia

Dis Colon Rectum. 2003 Oct;46(10):1332-6; discussion 1336-8.
J Clin Pathol. 1994 Nov;47(11):1032-4
Br J Obstet Gynaecol. 1998 Feb;105(2):206-10.
BJOG. 2000 May;107(5):594-9.

Spectrum of HPV-Related Diseases Recurrent Respiratory Papillomatosis

1. Bashai D, Kashima H, Shah K. 2000. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head neck Surg 126: 935-939.

2. Derkay CS. 1995. Task force on recurrent respiratory papillomas: a preliminary report. Arch Otolaryngol Head Neck Surg 121: 1386-1391.

3. Derkay CS, Darrow DH. 2000. Recurrent respiratory papillomatosis of larynx: current diagnosis and treatment. Otolaryngol Clin N Am 33: 1127-1141.

HIV-Positive Immunosuppression

4. Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, Eluf-Neto J, Castellsauge X, Meijer CJ, Van den Brule AJ, Franceschi S, Ashley R. 2002. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J natl Cancer Inst 94: 1604-1613.

5. Ferenczy A, Coutlee F, Franco E, Hankins C. 2003. Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. CMAJ 169: 431-434.

6. Weissenborn SJ, Funke AM, Hellmich M, Mallmann P, Fuchs PG, Pfister HJ, Wieland U. 2003. Oncogenic human papillomavirus DNA loads in human immunodeficiency virus-positive women with high-grade cervical lesions are strongly elevated. J clin Microbiol 41: 2763-2767.

7. Del Mistro A, Bianchi LC. 2001. HPPV-related neoplasias in HIV-infected individuals. Eur J Cancer 37: 127-1235.

8. Del Mistro A, Bianchi LC. 2001. HPPV-related neoplasias in HIV-infected individuals. Eur J Cancer 37: 127-1235.

9. Gillison ML, Shah KV. 2003. chapter 9: Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr 31: 57-65.

10. Centers for disease control and Prevention. 1999. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human-immuno-deficiency virus infection and acquired immunodeficiency syndrome. MMWR 48(NO.RR-13).

Leep Failures in Women with Cervical Dysplasia

11. Flannelly G, Langham H, Jandial L, Mana E, Campbell M, Kitchener H. 1997. A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. British Journal of Obstetrics and Gynaecology 104: 6-718-722

Abstract presented at SENTAC (Society for Ear, Nose, and Throat Advances in Children) October 31, 2003

HspE7 Treatment of Pediatric Recurrent Respiratory Papillomatosis (RRP): Interim Results utilizing a Laryngeal Staging and Severity Scale (LSSS) (Abstract)

Poster presented at 43rd ICAAC September 16, 2003

HspE7 Treatment of Pediatric Recurrent Respiratory Papillomatosis (RRP): Interim Results of an Open-Label Trial (Acrobat PDF File)

Abstract presented at CSSI 2003 Conference held in Quebec, Canada, September 9 th to 14 th , 2003

Heat shock fusion proteins: A new therapeutic vaccine platform.

Expert Opinion Biol Ther. 2003 Jun;3(3) :477-86

Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease

Chu NR (1)

1)	Stressgen Biotechnologies Corporation, 350, 4243 Glanford Ave. Victoria, BC, Canada V8Z 4B9

Abstract presented at the Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy - Walker's Cay, Bahamas, March 5 th to 8 th , 2003

Immunotherapy of HPV-Induced Diseases by HspE7, a Heat Shock Fusion Protein

Abstract presented at 15th Biennial Congress of the International Society for Sexually Transmitted Diseases Research (ISSTDR)

Determination of IgG Antibodies to SGN-00101 (HspE7) in Sera from Patients with HPV-Induced Dysplasia Treated with HspE7

Wiebe E. (1), Boux H. (2), Winnett M. (2), Rowse G. (1), Neefe J. (2), Siegel M.I. (2)

1)
2)

Stressgen Biotechnologies Corporation, Victoria, BC, Canada
Stressgen Biotechnologies Inc., Collegeville, PA, USA

Abstract presented at Symposium on Human Papillomavirus Vaccines

Importance of Tir4 in the Induction of Innate and Cellular Immunity by HspE7

Chu N.R. (1), Liu H. (1), Rechtenwald A. (1), Mizzen L. (1), Rowse G. (1), Siegel M.I. (2)

1)
2)

Stressgen Biotechnologies Corporation, Victoria, BC, Canada
Stressgen Biotechnologies Inc., Collegeville, PA, USA

Abstract presented at Development of Therapeutic Cancer Vaccines, Los Angeles, CA

CoValTM Fusions: A Therapeutic Vaccine Platform Utilizing Heat Shock Proteins (Hsp) to Treat Chronic Viral Infection and Cancer

Neefe, J.R. (1)

1)	Stressgen Biotechnologies, Collegeville, PA, USA

Abstract presented at Sixth Annual Conference on Vaccine Research, Arlington, VA

An Hsp65-HBV Core Antigen Fusion Protein Primes HBcAg-Specific CTL Responses in Immunologically Tolerant HBV Transgenic Mice

L.S.D. Anthony(1), S.G. Winslow(2), H. Liu(1), G. Rowse(1), B.Wu(1), A. Recktenwald(1), J.G. Julander(2), L.A. Mizzen(1), J.D. Morrey(2), M.I. Siegel(3)

1)	Stressgen Biotechnologies Corporation, Victoria, BC Canada
2)	Utah State University, Logan UT, USA
3)	Stressgen Biotechnologies Inc., Collegeville, PA, USA

J Immunol 2002 (November); 169(9):5300-5307

Effect of microbial heat shock proteins on airway inflammation and hyperresponsiveness

Rha Y.H. (1), Taube C. (1), Haczku A. (1), Joetham A. (1), Takeda K. (1), Duez C. (1), Siegel M. (2), Aydintug M.K. (3), Born W.K. (3), Dakhama A. (1), Gelfand E.W. (1)

1)	Dept. of Pediatrics, National Jewish Medical and Research Center, Denver, CO, USA
2)	Stressgen Biotechnologies, Collegeville, PA, USA
3)	Dept. of Immunology, National Jewish Medical and Research Center, Denver, CO, USA

Abstract presented at HPV 2002 - Paris, France

A Mechanism For The Immunotherapeutic Potential Of HspE7: Integration Of Innate And Adaptive Immunity

Chu, N.R. (1), Liu, H. (1), Wu, B. (1), Recktenwald, A. (1), Rowse, G. (1), Boux, H.A. (1), Boux, L.(2), Mizzen, L. (1) and Siegel, M.I.(2)

1)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
2)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Abstract presented at HPV 2002 - Paris, France

Durable Clearance Of Genital Warts Following Hspe7 Immunization

Goldstone, S. (1), Fife, K. (2), Fine P (3), Hagensee, M. (4), Palefsky, J. (5), Neefe, J. (6)

1)	Mt. Sinai School of Medicine, NY, USA
2)	Indiana Univ., Indianapolis, USA
3)	Baylor, Houston, USA
4)	LSUHSC, New Orleans, USA
5)	UCSF, San Francisco, USA
6)	Stressgen Biotechnologies, Inc., San Diego, CA, USA

Abstract presented at HPV 2002 - Paris, France

HspE7 Treatment Of High-Grade Anal Dysplasia: Final Results Of An Open-Label Trial And Interim Long-Term Follow-Up

Palefsky J. (1), Goldstone S. (2), Neefe J. (3)

1)	University of California at San Francisco, San Francisco, CA USA
2)	Mt. Sinai School of Medicine, New York City, NY USA
3)	Stressgen Biotechnologies Inc., Collegeville, PA, USA

Abstract presented at 5th Annual Conference on Vaccine Research - Baltimore, MD, USA - May 6-8, 2002

Mycobacterial Heat Shock Protein (Hsp) Fusions: A Novel Class of Immunotherapeutics for the Treatment of Human Papillomavirus (HPV) Infection

Chu, N.R. (1), Wu B. (1), Liu H. (1),; Wisniewski J. (1), Recktenwald A. (1), Rowse G. (1), Boux H.A. (1), Boux L. (2), Mizzen L. (1), Siegel M.I. (2)

1)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
2)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Abstract presented at 5th Annual Conference on Vaccine Research - Baltimore, MD, USA - May 6-8, 2002

Induction of HBcAg-Specific CTL Responses by a Heat Shock Protein Fused to the Core Antigen of the Hepatitis B Virus

Anthony L.S.D. (1), Liu H. (1), Rowse G. (1), Wu B. (1), Recktenwald A. (1), Mizzen L.A. (1), Boux H. (1) and Siegel M.I. (2)

1)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
2)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Abstract presented at 5th Annual Conference on Vaccine Research - Baltimore, MD, USA - May 6-8, 2002

Liu H. (1), Rowse G. (1), Chu N.R. (1), Wu B. (1), Boux H. (1) and Siegel M.I. (2)

HLA-A2 and H-2Db-restricted CTL activity induced by SGN-00101--a fusion protein comprised of heat shock protein and human papillomavirus E7

1)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
2)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Abstract presented at 5th Annual Conference on Vaccine Research - Baltimore, MD, USA - May 6-8, 2002

Rowse G. (1), Chu N.R. (1), Wiebe E. (1), Recktenwald A. (1), Mizzen L. (1), Boux H. (1) and Siegel M.I. (2)

Immunostimulatory actions of SGN-00101 and the separation of these effects from Lipopolysaccharide

1)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
2)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Dis Colon Rectum 2002 April; 45 (4) :502-7

Activity of HspE7, a Novel Immunotherapy, in Patients with Anogenital Warts (PDF)

Goldstone S. (1), Palefsky J. (2), Winnett M. (3), Neefe J. (3)

1)	Mt. Sinai School of Medicine, New York City, NY, USA
2)	University of California at San Francisco, San Francisco, CA, USA
3)	Stressgen Biotechnologies Inc., Collegeville, PA, USA

Dermatology Times (Vol. 23 No. 2, February 2002)

Cheryl Guttman

Novel vaccine promising in treatment of genital warts (PDF)

Staff Correspondent

Int Immunol 2002 Jan;14(1):23-30

How do cultured CD8(+) murine T cell clones survive repeated ligation of the TCR?

Abstract presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ASM's Annual Meeting on Infectious Diseases) - Chicago, IL, USA - December 18, 2001

J. M. Palefsky (1), S. E. Goldstone (2), M. Winnett (3), M. I. Siegel (3), J. R. Neefe (3)

HspE7 Treatment of Anal Dysplasia: Results of an Open Label Trial of HspE7 and Comparison with a Prior Controlled Trial of Low Dose HspE7 (PDF)

1)	University of California at San Francisco, San Francisco, CA USA
2)	Mt. Sinai School of Medicine, New York City, NY USA
3)	Stressgen Biotechnologies Inc., Collegeville, PA, USA

J Neurochem 2001 (October) 79(2): 311-318

Activation of MKK6, an upstream activator of p38, in Alzheimer's disease.

19th International Papillomavirus Conference - Florianopolis, Brazil - September 3, 2001

Stephen E. Goldstone (1), John R. Neefe (2), Mark T. Winnett (2), Joel M. Palefsky (3)

HspE7 Treatment of High Grade Anal Dysplasia: Updated Results of an Ongoing Open Label Trial

1)	Mt. Sinai School of Medicine, New York City, NY, USA
2)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA
3)	University of California at San Francisco, San Francisco, CA, USA

Abstract presented at American Society for Colon and Rectal Surgeons 2001 Annual Meeting - San Diego, CA June 2-7, 2001 as printed in Dis Colon Rectum 2001 44(4): A5-A26

Activity of HspE7 in patients with anogenital warts

Abstract presented at ATS 2001 (American Thoracic Society) - San Francisco, CA, USA - May 18-23, 2001 as printed in Am J Respir Crit Care Med 2001; 163(5): 243

Mycobacterium bovis BCG heat shock protein (BCG-HSP) / ovalbumin (OVA) fusion protein is more effective than free BCG-HSP in preventing allergic airway inflammation and airway hyperresponsiveness

Rha Y.H. (1), Joetham A. (1), Takeda K. (1), Duez C. (1), Balhorn A. (1), Dakhama A. (1), Siegel M.I. (2), Gelfand E.W. (1)

1)	Dept. of Pediatrics, National Jewish Medical and Research Center, Denver, CO, USA
2)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Abstract presented at ATS 2001 (American Thoracic Society) - San Francisco, CA, USA - May 18-23, 2001 as printed in Am J Respir Crit Care Med 2001; 163(5): A522

Mycobacterium leprae HSP 65kD prevents ragweed-induced airway hyperresponsiveness in a murine model of asthma

Santeliz J.V. (1), Winnett M. (2), Wills-Karp M. (3)

1)	Dept. of Environmental Health Sciences, Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, USA
2)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA
3)	Children's Hospital Medical Center, Cincinnati, OH, USA

Abstract presented at the 5th AIDS Malignancy Conference - Bethesda, Maryland, USA April 23-25, 2001

Preliminary data from an open label study of HspE7 treatment of anal HSIL

Palefsky J.M. (1), Goldstone S.E. (2), Neefe J.R. (3)

1)	University of California, San Francisco, CA, USA
2)	Mt. Sinai School of Medicine, New York, NY, USA
3)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Acta Neuropathol 2001 (April) 101(4): 305-310

Abortive apoptosis in Alzheimer's disease.

Abstract presented at Experimental Biology 2001 - Orlando, Florida, USA March 31-April 4, 2001 as printed in FASEB J 2001 Volume 15 Number 5: page A1006

Priming of HBV core antigen-specific CTL activity by immunization with a HBcAg-heat shock protein fusion protein

Liu H. (1), Anthony L.S.D. (1), Rowse G.J. (1), Recktenwald A. (1), Siegel M.I. (2), Mizzen L.A. (1)

1)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
2)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

J Neurochem 2001 (January) 76(2): 435-441

Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease.

Poster & Abstract presented at Keystone Symposia: Interfaces between Innate and Adaptive Immunity - Keystone, CO, USA - January 22-27, 2001

Innate immune recognition of the immunotherapeutic fusion protein HspE7

Chu N.R. (1), Bantroch S. (1), Wiebe E. (1), Cho B.K. (2), Palliser, D. (2), Boux L. (3), Siegel, M.I. (3), Mizzen L. (1)

1)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
2)	Center for Cancer Research, MIT, Cambridge, MA, USA
3)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Neurobiol Aging 2000 (November-December) 21(6): 807-813

Neuronal CDK7 in hippocampus is related to aging and Alzheimer disease.

Cell Stress Chaperones. 2000 Nov;5(5):401-5.

Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7.

Abstract presented at the 2nd International Conference on Heat Shock Proteins in Immune Response - Farmington, CT October 8-12, 2000

Response to anal dysplasia to treatment with HspE7

J Neuropathol Exp Neurol 2000 (October) 59(10): 880-888

Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease.

Abstract presented at Cancer Vaccines 2000 - New York, NY, USA - October 2-4, 2000:

Pathological response to treatment with HspE7 in anal dysplasia of multiple HPV types

Palefsky J.M. (1), Goldstone S.E. (2), Boux L.J. (3), Neefe J.R. (3)

1)	University of California, San Francisco, CA, USA
2)	Mt. Sinai School of Medicine, New York, NY, USA
3)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Abstract presented at Cancer Vaccines 2000 - New York, NY, USA - October 2-4,
2000

Immunotherapy in a K14-HPV16 Transgenic Model of Cervical Carcinogenesis by Administration of a Fusion Protein Comprising Mycobacterium bovis Bacille Calmette-Guerin (BCG) Hsp65 and HPV16 E7 (HspE7)

Daniel D. (1), Hanahan D. (1), Chu N.R. (2), Wu H.B. (2), Boux L. (3), Siegel M.I. (3), Mizzen L.A. (2)

1)	Hormone Research Institute, Dept. of Biochem. and Biophysics, University of California San Francisco, San Francisco, CA, USA
2)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
3)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Clin Exp Immunol 2000 121(2): 216-225

Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7

Chu N.R. (1), Wu H.B. (1), Wu T. (2), Boux L.J.(2), Siegel M.I. (2), Mizzen L.A. (1)

1)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
2)	Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
3)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Int J Dev Neurosci 2000 (July-August) 18(4-5): 433-437

Activation of oncogenic pathways in degenerating neurons in Alzheimer disease.

Abstract presented at HPV 2000 - 18th International Papillomavirus Conference - Barcelona, Spain July 23-28, 2000

Clinical and pathological response in a Phase II trial (SGN-00101-9902) of HspE7 in high grade anal dysplasia

Goldstone S.E. (1), Thompson J.A. (2), Neefe J.R. (3)

1)	Mt. Sinai School of Medicine, New York, NY, USA
2)	Impath, Los Angeles, CA, USA
3)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Abstract presented at 18th International Papillomavirus Conference -
Barcelona, Spain - July 23-28, 2000

Single Dose Subcutaneous Administration of HspE7 Induced Lymphoproliferative Responses to HPV 16 E7 in Healthy Volunteers

Kadish A.S. (1), Ho G.Y.F (1), Wang Y. (1), He W. (1), Chu N.R. (2), Winnett M.T. (2), Mizzen L.A. (2), Siegel M.I. (3), Neefe J.R. (3), et al.

1)	Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA
2)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
3)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Abstract presented at 18th International Papillomavirus Conference -
Barcelona, Spain- July 23-28, 2000

Innate immune recognition of the novel immunotherapeutic fusion protein HspE7 (BCG Hsp65 fused with HPV16 E7)

N.R. Chu (1), S. Bantroch(1), E. Wiebe (1), B.K. Cho (2), D. Palliser (2), H.N. Eisen (2), L. Boux (1), M.I. Siegel (3), and L. Mizzen (1).

1)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
2)	Center for Cancer Research, MIT, Cambridge, MA, USA
3)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA

Abstract presented at American Society of Clinical Oncology 36th Annual
Meeting - New Orleans, LA, USA - May 20-23, 2000 as published in 2000 American
Society of Clinical Oncology Programs/Proceedings Volume 19 Abstract
#1789

Antigen-Specific Cell-Mediated Immunity in a Phase I Dose-Escalation Trial of Single Doses of HspE7 in Healthy Volunteers

Kadish A.S. (1), Ho G. (1), Wang Y. (1), He W. (1), Chu N.R. (2), Winnett M. (3), Talluri K. (4), Mizzen L. (2), Siegel M.I. (3), Neefe J.R. (3)

1)	Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA
2)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
3)	Stressgen Biotechnologies, Inc., Collegeville, PA, USA
4)	PPD Development, Morrisville, NC, USA

Abstract presented at AAAAI 56th Annual Meeting - San Diego, CA, USA - March 3-8, 2000 as printed in J Allergy Clin Immunol 105 (1 part 2): S115

Treatment with adjuvant-free fusion protein comprised of M. bovis BCG Hsp65 and HPV16 E7 induces cell-mediated anti-tumor immunity

Chu N.R., Wu B., Bantroch S., Sweet H., Boux L., Siegel M., Mizzen, L.

Stressgen Biotechnologies Corporation, Victoria, BC, Canada

Immunity 2000 (March) 12(3): 263-272

A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins

Cho B.K. (1), Palliser D. (1), Guillen E. (2), Wisniewski J. (3), Young R.A. (2), Chen J. (1), Eisen H.N. (1)

1)	Center for Cancer Research and Dept. of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA
2)	The Whitehead Institute, Cambridge, MA, USA
3)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada

Abstract presented at Keystone Symposia: Cellular Immunity and Immunotherapy of Cancer - Santa Fe, NM January 21-27, 2000

Treatment with adjuvant-free fusion protein comprised of M. bovis BCG Hsp65 and HPV16 E7 induces cell-mediated anti-tumor immunity.

Vaccine 2000 (January) 17(4): 373-383

Priming of CD8+ CTL effector cells in mice by immunization with a stress
protein-influenza virus nucleoprotein fusion molecule

Anthony L.S., Wu H., Sweet H., Turnnir C., Boux L.J., Mizzen L.A.

Stressgen Biotechnologies Corporation, Victoria, BC, Canada

Exp Hematol 1999 (November); 27(11): 1627-1636

Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells

Multhoff G.(1), Mizzen L.(2), Winchester C.C.(3), Milner C.M.(3), Wenk S.(4), Eissner G.(1), Kampinga H.H.(5), Laumbacher B.(6), Johnson J.(6)

1)	Dept. of Hematology/Internistic Oncology, University Hospital Regensberg, Regensberg, Germany
2)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
3)	Dept. of Biochemistry, MRC Immunochemistry Unit, Oxford, United Kingdom
4)	GSF-Institute of Molecular Immunology, KKG Hyperthermia, Munich, Germany
5)	Dept. of Radiobiology, University of Groningen, Groningen, The Netherlands
6)	LMU Munich, Institute of Immunology, Munich, Germany

Abstract presented at 17th International Papillomavirus Conference - Charleston, SC, USA - January 9-15, 1999

Immunotherapy of Human Papillomavirus Type 16 associated carcinoma using adjuvant-free, fusion protein encoding M. bovis BCG Hsp65 and HPV16 E7

Chu N.R. (1), Wu B. (1), Bantroch S. (1), Wu T.C.(2) Boux L. (1), Siegel M. (1), Mizzen L. (1)

1)	Stressgen Biotechnologies Corporation, Victoria, BC, Canada
2)	Dept. of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA

Arterioscler Thromb Vasc Biol 1999 (August) 19(8): 1905-1911

Inhibition of arteriosclerosis by T-cell depletion in normocholesterolemic rabbits immunized with heat shock protein 65.

Abstract presented at Cancer Vaccine Week 1998 - New York, NY October 5-9, 1998

Cancer Immunotherapy using adjuvant-free, fusion protein encoding M. bovis BCG hsp65 and HPV16 E7

Abstract presented at 6th International Expert Forum on Immunotherapy and Gene Therapy - Florence, Italy May 6-8, 1998

Cancer Immunotherapy using adjuvant-free, fusion protein encoding M. bovis BCG hsp65 and HPV16 E7

Abstract presented at Experimental Biology 98 – San Francisco, CA April 18-22, 1998

Priming of CD8+ CTL with a heat shock-influenza nucleoprotein fusion molecule.

Abstract presented at Experimental Biology 98 - San Francisco, CA April 18-22, 1998 as printed in FASEB J 1998 12(5 part 2): A909

Cancer Immunotherapy using adjuvant-free, fusion protein encoding M. bovis BCG hsp65 and HPV16 E7

Abstract presented at International Conference on Dynamics and Regulation of the Stress Response - Kyoto, Japan March 9-12, 1998

Cancer Immunotherapy using adjuvant-free, fusion protein encoding M. bovis BCG hsp65 and HPV16 E7

Abstract presented at IBC's 5th International Conference on Vaccine Technologies - Washington, DC February 9-11, 1998

Cancer Immunotherapy using adjuvant-free, fusion protein encoding M. bovis BCG hsp65 and HPV16 E7

Atherosclerosis 1997 (January) 128(1): 27-38

Macrophage-lysis mediated by autoantibodies to heat shock protein 65/60.

Cell Stress Chaperones 1996 (April) 1(1): 29-32

Review of patents in the cell stress and chaperone field.

Biotherapy 1998 10(3): 173-189

Immune responses to stress proteins: applications to infectious disease and cancer

Mizzen L.

Stressgen Biotechnologies Corporation, Victoria, BC, Canada

sitemap

contact